195 related articles for article (PubMed ID: 21807779)
1. Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis.
Scarsi M; Ziglioli T; Airo' P
J Rheumatol; 2011 Oct; 38(10):2105-11. PubMed ID: 21807779
[TBL] [Abstract][Full Text] [Related]
2. Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response.
Scarsi M; Ziglioli T; Airò P
J Rheumatol; 2010 May; 37(5):911-6. PubMed ID: 20231200
[TBL] [Abstract][Full Text] [Related]
3. Reduced numbers of circulating CD28-negative CD4+ cells in patients with rheumatoid arthritis chronically treated with abatacept.
Gómez-García L; Ramírez-Assad C; Vargas A; Massó F; Sánchez-Muñoz F; Márquez-Velasco R; Amezcua-Guerra LM; Bojalil R
Int J Rheum Dis; 2013 Aug; 16(4):469-71. PubMed ID: 23992270
[No Abstract] [Full Text] [Related]
4. Abatacept therapy reduces CD28+CXCR5+ follicular helper-like T cells in patients with rheumatoid arthritis.
Fukuyo S; Nakayamada S; Iwata S; Kubo S; Saito K; Tanaka Y
Clin Exp Rheumatol; 2017; 35(4):562-570. PubMed ID: 28516880
[TBL] [Abstract][Full Text] [Related]
5. Role of abatacept in the management of rheumatoid arthritis.
Nogid A; Pham DQ
Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
[TBL] [Abstract][Full Text] [Related]
6. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis.
Korhonen R; Moilanen E
Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):276-84. PubMed ID: 19228144
[TBL] [Abstract][Full Text] [Related]
7. Reduction of peripheral blood T cells producing IFN-γ and IL-17 after therapy with abatacept for rheumatoid arthritis.
Scarsi M; Zanotti C; Chiarini M; Imberti L; Piantoni S; Frassi M; Tincani A; Airò P
Clin Exp Rheumatol; 2014; 32(2):204-10. PubMed ID: 24428959
[TBL] [Abstract][Full Text] [Related]
8. T-cell agents in the treatment of rheumatoid arthritis.
Solomon GE
Bull NYU Hosp Jt Dis; 2010; 68(3):162-5. PubMed ID: 20969545
[TBL] [Abstract][Full Text] [Related]
9. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M
J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of granzyme B decrease in patients with rheumatoid arthritis responding to abatacept.
Colombo E; Scarsi M; Piantoni S; Tincani A; Airò P
Clin Exp Rheumatol; 2016; 34(1):37-41. PubMed ID: 26633185
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus seropositivity is associated with the expansion of CD4+CD28- and CD8+CD28- T cells in rheumatoid arthritis.
Hooper M; Kallas EG; Coffin D; Campbell D; Evans TG; Looney RJ
J Rheumatol; 1999 Jul; 26(7):1452-7. PubMed ID: 10405929
[TBL] [Abstract][Full Text] [Related]
13. Abatacept mechanism of action: concordance with its clinical profile.
Herrero-Beaumont G; Martínez Calatrava MJ; Castañeda S
Reumatol Clin; 2012; 8(2):78-83. PubMed ID: 22104048
[TBL] [Abstract][Full Text] [Related]
14. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.
Ruderman EM; Pope RM
Arthritis Res Ther; 2005; 7 Suppl 2(Suppl 2):S21-5. PubMed ID: 15833145
[TBL] [Abstract][Full Text] [Related]
15. Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists.
Scheinfeld N
J Dermatolog Treat; 2006; 17(4):229-34. PubMed ID: 16971318
[TBL] [Abstract][Full Text] [Related]
16. Synovium infiltrating T cells induce excessive synovial cell function through CD28/B7 pathway in patients with rheumatoid arthritis.
Shimoyama Y; Nagafuchi H; Suzuki N; Ochi T; Sakane T
J Rheumatol; 1999 Oct; 26(10):2094-101. PubMed ID: 10529123
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry.
Berner B; Akça D; Jung T; Muller GA; Reuss-Borst MA
J Rheumatol; 2000 May; 27(5):1128-35. PubMed ID: 10813277
[TBL] [Abstract][Full Text] [Related]
18. The inhibitor of costimulation of T cells: abatacept.
Iannone F; Lapadula G
J Rheumatol Suppl; 2012 Jul; 89():100-2. PubMed ID: 22751606
[TBL] [Abstract][Full Text] [Related]
19. Cell surface CD28 levels define four CD4+ T cell subsets: abnormal expression in rheumatoid arthritis.
Salazar-Fontana LI; Sanz E; Mérida I; Zea A; Sanchez-Atrio A; Villa L; Martínez-A C; de la Hera A; Alvarez-Mon M
Clin Immunol; 2001 May; 99(2):253-65. PubMed ID: 11318597
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors of abatacept therapy discontinuation in patients with rheumatoid arthritis.
Piantoni S; Colombo E; Tincani A; Airò P; Scarsi M
Clin Rheumatol; 2016 Apr; 35(4):1065-9. PubMed ID: 26809797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
